Clinical, Morphological and Clonal Progression of VEXAS Syndrome in the Context of Myelodysplasia Treated with Azacytidine
Authors:
Open Access
- 12 May 2022
- journal article
- other
- Published by SAABRON PRESS in Clinical Hematology International
- Vol. 4 (1-2) , 52-55
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Clinical significance of somatic mutation in unexplained blood cytopeniaBlood, 2017
- Development and validation of a comprehensive genomic diagnostic tool for myeloid malignanciesBlood, 2016
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemiaBlood, 2016
- Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromesBlood, 2015
- Prevalence and possible causes of anemia in the elderly: a cross-sectional analysis of a large European university hospital cohortClinical Interventions in Aging, 2014
- The genetic basis of myelodysplasia and its clinical relevanceBlood, 2013
- Clinical and biological implications of driver mutations in myelodysplastic syndromesBlood, 2013
- Clinical Effect of Point Mutations in Myelodysplastic SyndromesNew England Journal of Medicine, 2011
- Association of mild anemia with hospitalization and mortality in the elderly: the Health and Anemia population-based studyHaematologica, 2009
- Racial variation in the relationship of anemia with mortality and mobility disability among older adultsBlood, 2007